1. Scrip
  2. >>Therapy Areas
  3. >>Anticancer

ASH: J&J Banks On Lack Of Differentiation Syndrome With Menin Inhibitor

 
• By Alaric DeArment

In an interview at the conference, a J&J exec noted that bleximenib in frontline AML did not show differentiation syndrome or QTc prolongation.

(Alaric DeArment/Scrip)

Although last month Syndax Pharmaceuticals became the first company to win approval for a menin inhibitor from the US Food and Drug Administration, Johnson & Johnson is confident that it has a winner among the class in particular based on the safety profile seen in Phase I data for bleximenib presented at the recently concluded American Society of Hematology meeting, but it faces some stiff competition.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Anticancer

In Brief: Boehringer Ingelheim, Tessellate Bio Link For Precision Therapies For ALT Tumors

 
• By Sushmita Panda

In its first pharma collaboration, Tessellate Bio has inked a deal potentially worth more than €500m with Boehringer Ingelheim for therapies for ALT tumors.

Data From China Bolster Summit/Akeso’s Case For Ivonescimab

 
• By Alaric DeArment

Results from the Phase III HARMONi-6 trial showed the PD-1/VEGF bispecific antibody beating out BeiGene’s Tevimbra in NSCLC.

Gilead Set To Expand Trodelvy/Keytruda Into Frontline TNBC

 
• By Alaric DeArment

The company reported positive topline results for ASCENT-04, which also bode well for the ASCENT-03 trial in patients with low PD-L1 expression.

Enhertu Takes The First-Line Throne In HER2 Metastatic Breast Cancer

 
• By Jessica Merrill

AstraZeneca and Daiichi’s DESTINY-Breast09 trial testing Enhertu with pertuzumab versus standard of care showed a statistically significant and meaningful PFS improvement.

More from Conferences

Lexicon Has A Lot Riding On LX9211 Phase IIb Readout In Pain

 
• By Jessica Merrill

CEO Mike Exton talked to Scrip about moving the company forward after a disappointingly disruptive 2024.

Reflections From Biotech Leader John Maraganore

 
• By Jessica Merrill

The founder and director of City Therapeutics and founding CEO of Alnylam discussed pressing issues facing the biotech sector in a fireside chat at the recent BIO CEO & Investor Conference.

M&A Takeoff May Be Delayed, Experts Predict

 
• By Jessica Merrill

All the elements for a big M&A year are in place, but political uncertainty and interest rates could push more deals into the second half of the year, according to business development experts at BIO CEO & Investor.